Patricia Inacio, PhD,  science writer—

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

New Solution For Repairing Misfolded Proteins in Alzheimer’s

A new study entitled “HSF-1–mediated cytoskeletal integrity determines thermotolerance and life span” published in Science unravels the role of heat shock transcription factor–1 (HSF-1) in aging and associated neurodegenerative diseases, such as Alzheimer’s. Heat shock proteins (HSP) are a group of proteins induced by heat…

Data For New Alzheimer’s Disease Treatment For Agitation To Be Presented at Upcoming ANA Meeting

Avanir Pharmaceuticals, Inc. will present their most-recent results from two clinical trials currently underway for treating conditions associated with Alzheimer’s disease (AD). The data is set to be presented at the American Neurological Association’s (ANA) Annual Meeting in Baltimore, Maryland, from October 12-14, 2014. The phase II clinical trial evaluated…

Pathway in Brain Contributes to Alzheimer’s Disease

A new study entitled “Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer’s Disease,” published in the online issue of Neuron, reports the discovery of a key pathway to the progression of Alzheimer’s Disease. Alzheimer’s disease is characterized by synaptic…

New Experimental Therapy For Alzheimer’s Agitation Shows Promise

Avanir Pharmaceuticals Inc. reported today new, positive results for their leading drug, AVP-923, designed to treat agitation in Alzheimer’s disease patients. The results will be presented at the American Neurological Association’s (ANA) 2014 Annual Meeting in Baltimore, MD, October 12-14, 2014. Joao Siffert, MD, chief medical officer at Avanir,…

Genetic Variant Identified As Risk Factor For Alzheimer’s

The identification of a genetic variant may lead to improved diagnostics for predicting the onset of Alzheimer’s disease. Amyloid-beta (Aβ) is the main component of amyloid plaques, i.e., extracellular deposits in the brains of patients with Alzheimer’s disease. Now, a new study entitled “Apolipoprotein E Genotype and…